Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock

$15.03

1.55% day before yesterday

NYSE, May 30, 10:10 pm CET

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock price

$15.03

-4.18 21.76% 5Y

NYSE, Closing price Fri, May 30 2025

+0.23 1.55%

ISIN

US8740602052

Symbol

TAK

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$46.78b
Enterprise Value	$75.31b
P/E (TTM) P/E ratio	31.98
EV/FCF (TTM) EV/FCF	15.29
EV/Sales (TTM) EV/Sales	2.37
P/S ratio (TTM) P/S ratio	1.47
P/B ratio (TTM) P/B ratio	0.49
Dividend yield	4.07%
Last dividend (FY24)	$0.61
Revenue growth (TTM) Revenue growth	7.45%
Revenue (TTM) Revenue	$31.81b
EBIT (operating result TTM) EBIT	$2.38b
Free Cash Flow (TTM) Free Cash Flow	$4.92b
Cash position	$2.82b
EPS (TTM) EPS	$0.47
P/E forward	27.70
P/S forward	1.48
EV/Sales forward	2.39
Short interest	0.20%

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Get Started for Free Today

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

8x Buy

53%

7x Hold

47%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast:

Buy

53%

Hold

47%

Analyst Estimates with Stock Price Targets

Financial data from Takeda Pharmaceutical Co. Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	31,805 31,805	7% 7% 100%
- Direct Costs	10,970 10,970	11% 11% 34%
Gross Profit	20,835 20,835	6% 6% 66%
- Selling and Administrative Expenses	7,669 7,669	5% 5% 24%
- Research and Development Expense	5,069 5,069	0% 0% 16%
EBITDA	6,646 6,646	4% 4% 21%
- Depreciation and Amortization	4,268 4,268	18% 18% 13%
EBIT (Operating Income) EBIT	2,378 2,378	14% 14% 7%
Net Profit	749 749	25% 25% 2%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stock News

Neutral

Business Wire

●

about 7 hours ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a...

Neutral

Business Wire

●

5 days ago

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Applications are now open for the Takeda Innovators in Science Award with Nature recognizing the groundbreaking research of early-career scientists.

Neutral

Business Wire

●

18 days ago

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin defici...

More Takeda Pharmaceutical Co. Ltd. Sponsored ADR News

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Head office	Japan
CEO	Christophe Weber
Employees	49,281
Founded	1781
Website	www.takeda.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now